Literature DB >> 28167598

In Vitro Sensitivity of Cutaneous Leishmania Promastigote Isolates Circulating in French Guiana to a Set of Drugs.

Marine Ginouvès1,2, Stéphane Simon2,1, Mathieu Nacher2,3, Magalie Demar2,1,4, Bernard Carme2, Pierre Couppié2,5, Ghislaine Prévot2.   

Abstract

AbstractAnti-leishmaniasis drug resistance is a common problem worldwide. The aim of this study was to inventory the general in vitro level of sensitivity of Leishmania isolates circulating in French Guiana and to highlight potential in vitro pentamidine-resistant isolates. This sensitivity study was conducted on 36 patient-promastigote isolates for seven drugs (amphotericin B, azithromycin, fluconazole, meglumine antimoniate, miltefosine, paromomycin, and pentamidine) using the Cell Counting Kit-8 viability test. The IC50 values obtained were heterogeneous. One isolate exhibited high IC50 values for almost all drugs tested. Pentamidine, which is the first-line treatment in French Guiana, showed efficacy at very low doses (mean of 0.0038 μg/mL). The concordance of the in vitro pentamidine results with the patients' clinical outcomes was 94% (K = 0.82).

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28167598      PMCID： PMC5417208          DOI： 10.4269/ajtmh.16-0373

Source DB:  PubMed          Journal:  Am J Trop Med Hyg        ISSN： 0002-9637            Impact factor:   2.345


  50 in total

1.  Seasonal fluctuations of incubation, healing delays, and clinical presentation of cutaneous leishmaniasis in French Guiana.

Authors:  M Nacher; B Carme; D Sainte Marie; P Couppié; E Clyti; P Guibert; R Pradinaud
Journal:  J Parasitol       Date:  2001-12       Impact factor: 1.276

2.  Treatment failure in children in a randomized clinical trial with 10 and 20 days of meglumine antimonate for cutaneous leishmaniasis due to Leishmania viannia species.

Authors:  R Palacios; L E Osorio; L F Grajalew; M T Ochoa
Journal:  Am J Trop Med Hyg       Date:  2001 Mar-Apr       Impact factor: 2.345

3.  Superior efficacy of oral fluconazole 400 mg daily versus oral fluconazole 200 mg daily in the treatment of cutaneous leishmania major infection: a randomized clinical trial.

Authors:  Maryam Emad; Fariborz Hayati; Mohammad Kazem Fallahzadeh; Mohammad Reza Namazi
Journal:  J Am Acad Dermatol       Date:  2011-03       Impact factor: 11.527

4.  Evidence that the high incidence of treatment failures in Indian kala-azar is due to the emergence of antimony-resistant strains of Leishmania donovani.

Authors:  R Lira; S Sundar; A Makharia; R Kenney; A Gam; E Saraiva; D Sacks
Journal:  J Infect Dis       Date:  1999-08       Impact factor: 5.226

5.  Successful topical treatment of murine cutaneous leishmaniasis with a combination of paromomycin (Aminosidine) and gentamicin.

Authors:  M Grogl; B G Schuster; W Y Ellis; J D Berman
Journal:  J Parasitol       Date:  1999-04       Impact factor: 1.276

6.  Axenically cultured amastigote forms as an in vitro model for investigation of antileishmanial agents.

Authors:  D Sereno; J L Lemesre
Journal:  Antimicrob Agents Chemother       Date:  1997-05       Impact factor: 5.191

7.  Generic sodium stibogluconate is as safe and effective as branded meglumine antimoniate, for the treatment of tegumentary leishmaniasis in Isiboro Secure Park, Bolivia.

Authors:  H Bermúdez; E Rojas; L Garcia; P Desjeux; J-C Dujardin; M Boelaert; F Chappuis
Journal:  Ann Trop Med Parasitol       Date:  2006-10

8.  In vitro activity of anti-leishmanial drugs against Leishmania donovani is host cell dependent.

Authors:  Karin Seifert; Patricia Escobar; Simon L Croft
Journal:  J Antimicrob Chemother       Date:  2010-01-20       Impact factor: 5.790

9.  Leishmania spp. identification by polymerase chain reaction-restriction fragment length polymorphism analysis and its applications in French Guiana.

Authors:  Stéphane Simon; Vincent Veron; Bernard Carme
Journal:  Diagn Microbiol Infect Dis       Date:  2009-09-25       Impact factor: 2.803

10.  Sensitivity of Leishmania braziliensis promastigotes to meglumine antimoniate (glucantime) is higher than that of other Leishmania species and correlates with response to therapy in American tegumentary leishmaniasis.

Authors:  Rilza B Gayoso Azeredo-Coutinho; Sergio C F Mendonça; Heather Callahan; Andréia C Portal; Grögl Max
Journal:  J Parasitol       Date:  2007-06       Impact factor: 1.276
View more
  7 in total

1.  Interaction of apigenin-7-O-glucoside with pyrimethamine against Toxoplasma gondii growth.

Authors:  Daniel A Abugri; William H Witola
Journal:  J Parasit Dis       Date:  2019-12-02

2.  Potency and Preclinical Evidence of Synergy of Oral Azole Drugs and Miltefosine in an Ex Vivo Model of Leishmania (Viannia) panamensis Infection.

Authors:  Olga Lucía Fernández; Mariana Rosales-Chilama; Natali Quintero; Bruno L Travi; Dawn M Wetzel; María Adelaida Gómez; Nancy Gore Saravia
Journal:  Antimicrob Agents Chemother       Date:  2021-10-25       Impact factor: 5.938

Review 3.  Of Drugs and Trypanosomatids: New Tools and Knowledge to Reduce Bottlenecks in Drug Discovery.

Authors:  Arijit Bhattacharya; Audrey Corbeil; Rubens L do Monte-Neto; Christopher Fernandez-Prada
Journal:  Genes (Basel)       Date:  2020-06-29       Impact factor: 4.096

4.  Outbreak of Cutaneous Leishmaniasis among military personnel in French Guiana, 2020: Clinical, phylogenetic, individual and environmental aspects.

Authors:  Kim Henry; Aurélie Mayet; Miguel Hernandez; Guillaume Frechard; Pierre-Antoine Blanc; Marion Schmitt; Nathalie André; Jean-Marie Loreau; Marine Ginouves; Ghislaine Prévot; Pierre Couppié; Magalie Demar; Romain Blaizot
Journal:  PLoS Negl Trop Dis       Date:  2021-11-19

5.  First report of Leishmania RNA virus 1 in Leishmania (Viannia) braziliensis clinical isolates from Rio de Janeiro State - Brazil.

Authors:  Anabel Zabala-Peñafiel; Maria Fantinatti; Geovane Dias-Lopes; Jéssica Leite da Silva; Luciana de Freitas Campos Miranda; Marcelo Rosandiski Lyra; Maria Inês Fernandes Pimentel; Fátima Conceição-Silva; Carlos Roberto Alves
Journal:  Mem Inst Oswaldo Cruz       Date:  2022-08-22       Impact factor: 2.747

6.  Intraspecies differences in natural susceptibility to amphotericine B of clinical isolates of Leishmania subgenus Viannia.

Authors:  Carlos Franco-Muñoz; Merab Manjarrés-Estremor; Clemencia Ovalle-Bracho
Journal:  PLoS One       Date:  2018-04-26       Impact factor: 3.240

7.  Green Synthesis of Antileishmanial and Antifungal Silver Nanoparticles Using Corn Cob Xylan as a Reducing and Stabilizing Agent.

Authors:  Rony Lucas Silva Viana; Gabriel Pereira Fidelis; Mayara Jane Campos Medeiros; Marcelo Antonio Morgano; Monique Gabriela Chagas Faustino Alves; Luiz Felipe Domingues Passero; Daniel Lima Pontes; Raquel Cordeiro Theodoro; Thales Domingos Arantes; Diego Araujo Sabry; Guilherme Lanzi Sassaki; Raniere Fagundes Melo-Silveira; Hugo Alexandre Oliveira Rocha
Journal:  Biomolecules       Date:  2020-08-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.